EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals

Juan P Vazquez iD, Corinne Pettigrew, Yuxin Zhu, Claire Anderson iD, Guray Erus, Christos Davatzikos, Michael Miller, Abhay Moghekar, Sungtaek Oh, Chan-Hyun Na, Marilyn Albert, Paul Worley und 1 weitere

Annals of Clinical and Translational Neurology · 2026

DOI: 10.1002/acn3.70216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2026. Verfasst von Juan P Vazquez und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: C-Reactive Protein, Nerve Tissue Proteins, Brain, Cognitive Dysfunction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neuronal pentraxin 2 (NPTX2) is a synaptic protein involved in synaptic plasticity and regulation of neuronal excitability. Lower baseline cerebrospinal fluid (CSF) NPTX2 levels have been shown to be associated with an earlier onset of mild cognitive impairment (MCI), a pre‐dementia syndrome, even after CSF Alzheimer's Disease (AD) biomarkers (amyloid beta (Aβ 42/40 ), and phosphorylated tau (p‐tau 181 )) were considered. To date, however, it is not known whether CSF NPTX2 levels among cognitively unimpaired individuals are associated with longitudinal brain atrophy. Objective(s) Evaluate the association between baseline CSF NPTX2 levels and measures of long‐term brain atrophy in participants who were cognitively unimpaired at baseline.

Methods

Analyses included 213 participants ( M baseline age = 57.2 years, 62% female) from the prospective longitudinal BIOCARD study with 13.9 years (max = 22.6 years) of magnetic resonance imaging (MRI) follow‐up, on average. CSF NPTX2 was measured as a composite of three correlated peptides obtained by quantitative parallel reaction monitoring mass spectrometry. MRI brain atrophy was measured longitudinally with three composites. This included two spatial patterns of atrophy: (1) a composite of AD‐signature regions (SPARE‐AD) and (2) a composite of regions sensitive to brain aging (SPARE‐BA), with higher values indicating more atrophy. Additionally, (3) a medial temporal lobe (MTL) composite included volumes of the amygdala, hippocampus, and entorhinal cortex. Linear mixed effect models assessed the association of baseline NPTX2 levels with the rate of change in the brain atrophy measures.

Results

When covarying biomarkers of AD pathology (i.e., the ratio of CSF p‐tau 181 /(Aβ 1‐42 /Aβ 1‐40 ), age, sex, APOE4 genetic status, and years of education), lower baseline NPTX2 levels were associated with greater atrophy over time in both AD‐vulnerable regions (SPARE‐AD, standardized estimate = −0.008, p = 0.034) as well as regions sensitive to brain aging (SPARE‐BA, standardized estimate = −0.011, p = 0.014). These associations were independent of participants having follow‐up diagnoses of MCI or dementia.

Conclusion

Our findings suggest that after accounting for biomarkers of AD pathology, CSF NPTX2 is associated with slower longitudinal atrophy in AD‐signature and aging‐related regions. These findings are consistent with the view that NPTX2 may be a resilience factor in the presence of pathology and modifies rates of neurodegeneration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-Reactive ProteinNerve Tissue ProteinsBrainCognitive DysfunctionHumansFemaleMaleAtrophyMiddle AgedAgedMagnetic Resonance ImagingBiomarkersLongitudinal StudiesAdulttau ProteinsAmyloid beta-Peptides

Stichwörter der Autor:innen

MRIagingbiomarkersdementia

Substanzen

C-Reactive ProteinNerve Tissue ProteinsBiomarkerstau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Centre for Biomedical Image Computing and Analytics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
  • Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Juan P Vazquez, Claire Anderson, Anja Soldan

Förderung

  • NIA NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute on Aging

Zitieren

APA

Vazquez, J. P., Pettigrew, C., Zhu, Y., Anderson, C., Erus, G., Davatzikos, C., Miller, M., Moghekar, A., Oh, S., Na, C. H., Albert, M., Worley, P., & Soldan, A. (2026). CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70216

Vancouver

Vazquez JP, Pettigrew C, Zhu Y, Anderson C, Erus G, Davatzikos C, et al. CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals. Annals of Clinical and Translational Neurology. 2026. doi:10.1002/acn3.70216

BibTeX
@article{Vazquez2026,
  author = {Vazquez, Juan P and Pettigrew, Corinne and Zhu, Yuxin and Anderson, Claire and Erus, Guray and Davatzikos, Christos and Miller, Michael and Moghekar, Abhay and Oh, Sungtaek and Na, Chan-Hyun and Albert, Marilyn and Worley, Paul and Soldan, Anja},
  title = {CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  doi = {10.1002/acn3.70216}
}
Kostenlos starten →